X线定位下ESWL治疗上尿路结石的临床疗效观察

目的：对X线定位下采用低能量体外冲击波碎石术（ESWL）的临床经验进行总结,为尿路结石的治疗提供指导。方法：回顾性分析2009年3月至2014年3月收治的60例上尿路结石患者治疗的临床资料,所有患者均实施X线定位下的ESWL治疗,其中肾脏结石18例,输尿管结石42例。结果：X线定位结石准确率为100%。一次碎石60例患者,有43例完全粉碎结石（71.67%）,二次碎石17例,完全粉碎结石14例（23.33%）,三次碎石3例,完全粉碎结石2例（3.33%）。有1例患者碎石失败,后采用开放手术成功取石。肾结石患者18例,最多经过三次碎石后有1例患者碎石失败,成功率为94.44%;输尿管结石患者42例,最多经过3次碎石,成功率为100%。碎石治疗后并发症主要为血尿,共有56例患者在术后出现血尿,经给予相关的止血药物治疗后3d消失。肾绞痛患者4例,经过解痉等对症治疗后缓解。结论：X线定位下采用低能量体外冲击波碎石术,对上尿路结石患者进行碎石治疗的成功率较高、创伤小,治疗后康复效果较好,值得临床推广。     

ESWL治疗上尿路结石1792例的护理总结

目的：探讨体外冲击波碎石（ESWL）治疗上尿路结石的护理方法。方法：回顾总结分析ESWL治疗上尿路结石1792例的术前宣教与术后观察护理。结果：详细手术方法宣教,可解除患者的心理压力,肠道准备可为碎石提供条件。结论：术后对症指导与观察能避免并发症的发生与发展。     

ESWL后促排治疗儿童尿路结石疗效观察

我院自1995年5月～2005年1月,应用JT--ESWL型体外震波碎石机碎石52例,其中碎石后促排治疗28例,效果满意。报告如下。     

148例学生患者上尿路结石的ESWL治疗分析

报道148例大、中、小学生上尿路结石的ESWL治疗。作者就其学生的特点,碎石中应注意的问题以及校医在院外排石期间的作用进行了讨论。     

泌尿系结石绞痛急诊行ESWL疗效观察

我院自1997～1999年应用体外冲击波碎石术(ESWL)治疗泌尿系结石817例,其中因肾结石输尿管结石绞痛发作急诊行ESWL94例,效果满意,无明显不良反应。现报告如下。 1 临床资料 1.1 一般资料本组94例,男53例,女41例。年龄16岁～74岁,平均42岁。病程1h至4d。其中85例曾行解痉止痛治疗绞痛缓解不明显,未行治疗9例。全部病例均有典型肾绞痛症状体征。均行B超检查,其中输尿管结石绞痛者73     

体外冲击波碎石术治疗上尿路结石至严重并发症10例临床分析

目的分析总结体外冲击波碎石术(extracorporeal shock wave lithotripsy,ESWL)治疗上尿路结石至严重并发症的原因及处理;方法对在行ESWL治疗上尿路结石时发生严重并发症9例患者的临床资料进行分析总结;结果 9例严重并发症包括肾包膜下巨大血肿2例,严重尿路感染2例,长段石街形成3例,严重血尿1例,肾功能严重受损1例;除1例肾功能严重受损未能恢复外,其它8例均预后良好;结论 ESWL治疗尿路结石所致严重并发症主要是因病例选择不当、操作不规范引起,处理应以抗感染、充分引流、保护肾功能为最高原则。     

α1肾上腺素能受体阻滞剂在上尿路结石ESWL治疗后辅助排石的作用

由于体外冲击波碎石术(ESWL)损伤小,被普遍认为是治疗上尿路结石的首选方法,但因排石过程慢,易反复出现肾绞痛等不适症状,ESWL的治疗效果一直受到争议.ESWL联合药物辅助排石,可提高ESWL的治疗效果,成为人们关注的课题.近来的临床研究显示,α1肾上腺素能受体阻滞剂有助于上尿路结石的排出.我们于2009年6月-2010年2月,共选取80例上尿路结石住院患者进行了随机对照分组研究,观察α1肾上腺素能受体阻滞剂坦索罗辛在上尿路结石ESWL后辅助排石中的作用,现将结果报告如下.     

体外冲击波碎石治疗上尿路结石的护理干预及效果观察

上尿路结石是泌尿外科常见病、多发病,其首选的治疗方法是低能量体外冲击波碎石.但由于体外冲击波碎石技术是现代新兴的技术,病人对此技术的知识、治疗效果缺乏了解,往往出现紧张、恐惧的心态,影响疗效.为了减轻病人的疼痛和减少并发症的发生,加强体外冲击波碎石治疗上尿路结石的护理非常重要,本文对此进行了探讨.     

输尿管软镜碎石术治疗上尿路结石患者的疗效和安全性

目的 探讨输尿管软镜碎石术治疗上尿路结石患者的临床疗效和安全性.方法 选取2017年3月至2019年12月天津市武清区人民医院收治的94例上尿路结石患者作为研究对象.入院后,94例患者均需接受输尿管软镜碎石术治疗,观察患者的手术治疗效果并详细记录术后并发症发生情况.结果 94例上尿路结石患者的一次性成功进镜率为90.4...     

绞痛期尿路结石体外碎石术的应用价值

体外冲击波碎石（ESWL）治疗已广泛应用于临床，对尿路结石疗效肯定，被公认为尿路结石首选治疗方法。我院自2006年1月-2009年3月应用ESWL治疗1365例尿路结石伴肾绞痛患者，取得良好效果，现报告如下。     

Immunogenicity and safety of a Trivalent Influenza HA vaccine in Indonesian infants and children

IntroductionHigh rate of influenza infection in children made influenza vaccination strongly recommended for all person aged >6 months in Indonesia. Bio Farma Trivalent Influenza HA (Flubio®) vaccine has been used in adolescents and adults, resulted in increased seroconversion, seroprotection rates and geometric mean titer (GMT). However, no data is available regarding its efficacy and safety in children. This study aimed to assess the immunogenicity and safety of Flubio® vaccine in infants and children.Materials and methodsThis was a phase II, open-labeled, clinical trial conducted on healthy children aged 6 month-11 years, vaccinated with 1 or 2 doses of Influenza HA vaccine, with a 28-day interval. Flubio® vaccine composed of A/California/7/2009 (H1N1) pandemic 09, A/Texas/50/2012 (H3N2), and B/Massachusetts/2/2012 strain. This study was held at East Jakarta, Indonesia from May until July 2014. A Total of 405 subjects were included and divided into three groups: A(6–35 months), B(3–8 years), and C(9–11 years). Antibody titer was measured at visit V1 (Day 0), V2 (28 days/+7days after the first dose) and V3 (28 days/+7days after second dose). The seroprotection and seroconversion rates were assessed. Safety was assessed up to 28 days following each dose.ResultsA total of 404 subjects completed the study. After vaccination, all subjects achieved seroprotection and increased seroconversion rates, with post-vaccination antibody titer of ≥1:40 HI for all strains. The GMT also increased significantly. Within 30 min after vaccination, 14.6% and 2% had local and systemic reactions; meanwhile, between 30 min to 72 h after vaccination, 35.1% and 13.6% subjects had local and systemic reactions, respectively. Most reactions were mild. No serious adverse event (SAE) was reported related to vaccine.ConclusionFlubio® (Influenza HA Trivalent) vaccine is immunogenic and safe for children aged 6 months-11 years.Trial Registration: The trial is registered at the US National Institutes of Health (ClinicalTrials.gov) #NCT02093260.     

Extracorporeal shock wave lithotripsy of pancreatic stones as a part of complex endoscopic therapy

INTRODUCTION: The authors report on ESWL treatment of 29 patients suffering from pancreatolithiasis. PATIENTS/METHODS: The mean age was 46.5 (23-76) years, there were 7 women and 22 men. The etiology of chronic calcifying pancreatitis was alcohol in 24 (82.7%) cases, idiopathic in 3 (10.3%) patients and there was one familiar and one pancreas divisum case. The indication of ESWL was abdominal pain in 27/29 (93.1%) cases. During ERCP pancreatic sphincterotomy was performed and a nasopancreatic catheter was placed for a continuous lavage with isotonic citrate at a rate of 0.5-1 ml/min for a mean of 6 days. The mean number of ESWLs was 2.2. RESULTS: Fragmentation was achieved in 28/29 (96.5%) patients. There were five (17.5%) complications, fever in three cases, one case of acute relapse of pancreatitis, and one hematuria. The mean number of therapeutic ERCPs was 2.32 (0-7). Overall a complete duct clearance was achieved in 62% (18/29) of the patients, partial clearance in 13.9% (4/29) but the ESWL was unsuccessful in 24.1% (7/29) of the cases. Early pain relief occurred in almost every case (28/29). Twenty four (82.7%) patients were followed for 18.7 (2-33) months. Each patient remained symptom free. The average weight gain was 7.6 kg. The exocrine pancreatic function determined by Lundh test in 7 patients had not improved (11.2 vs. 12.2 pathological value in average). Recurrence of pancreatic duct stones was revealed in four (22.2%) cases among the 18 successfully treated patients after 15 (7-22) months. CONCLUSION: The authors conclude that the ESWL treatment of pancreatic stones together with the endotherapy applied is an effective method for painful pancreatolithiasis.     

冻干无佐剂Vero细胞CTN狂犬病疫苗安全性和免疫原性研究

目的 观察人用冻干狂犬病疫苗(Vero细胞/CTN疫苗株)的安全性、免疫原性和抗体持久性.方法 对450名健康志愿者随机分为2组,300人(试验组)接种人用冻干狂犬病疫苗(Vero细胞/CTN疫苗株),150人(对照组)接种进口冻干无佐剂狂犬病纯化疫苗;按照0、3、7、14、28 d免疫程序;观察每针次接种后局部和全身反应.采用快速荧光灶抑制试验(RFFIT)检测0(首剂接种前)、3、7、14、28d血清中和抗体水平(GMT).首剂免疫后365 d采集试验组血样本212份,对照组血样本97份;首剂免疫后730 d采集试验组血样本176份,对照组血样本80份,RFFIT检测GMT.结果 所有接种对象均未出现严重局部和全身反应.首剂免疫后3、7、14、28、365和730 d试验组抗体阳转率分别为2.35%、80.78%、100.00%、100.00%、98.58%和73.30%;GMT分别为0.12、1.01、9.83、12.61、3.68和2.81 IU/ml.首剂免疫后3、7、14、28、365和730 d对照组抗体阳转率分别为4.00%、87.20%、100.00%、100.00%、97.94%和76.25%;GMT分别为0.13、1.18、10.24、11.61、4.18和1.92 IU/ml.所有结果试验组与对照组相比差异无统计学意义(P＞0.05).结论 人用冻干狂犬病疫苗具有良好的安全性、免疫原性和抗体持久性.     

体外冲击波碎石机治疗泌尿系结石568例临床疗效观察

目的探讨体外冲击波碎石机的治疗泌尿系结石的临床疗效。方法回顾性分析该院2008年3月—2011年3月收治的568例结石患者临床资料,所有患者均经体外冲击波碎石机治疗泌尿系统结石。结果经治疗,504例患者结石粉碎后全部排出体外,占88.7%;其中391例一次碎石成功（77.6%）,75例经过2次或3次排石成功（14.9%）,38例经过3次以上排石成功（7.5%）。64例碎石失败,改用其他方法治疗。结论体外冲击波碎石治疗输尿管结石疗效确切、不良反应小、操作方便可行。     

Contraceptive efficacy and safety of DMPA-SC

DMPA-SC 104 mg/0.65 mL is a new, low-dose subcutaneous (SC) formulation of Depo-Provera contraceptive injection (150 mg/mL medroxyprogesterone acetate injectable suspension) that provides efficacy, safety and immediacy of onset equivalent to Depo-Provera intramuscular (IM) injection. Two large, open-label, Phase 3 studies assessed the 1-year contraceptive efficacy, safety and patient satisfaction with DMPA-SC administered every 3 months (12-13 weeks). Zero pregnancies were reported in both studies, which included a total of 16,023 woman-cycles of exposure to DMPA-SC and substantial numbers of overweight or obese women. DMPA-SC was well-tolerated and adverse events were similar to those reported previously with Depo-Provera IM. Thus, DMPA-SC offers women a new, highly effective and convenient long-acting contraceptive option.     

甲基多巴及拉贝洛尔联合硫酸镁对重度早发型子痫前期患者的疗效及安全性分析

目的探讨甲基多巴联合拉贝洛尔治疗重度早发型子痫前期综合征的疗效及安全性。方法2叭1年3月—2014年9月本院共收治重度早发型子痫前期综合征患者82例,随机分成观察组和对照组,各41例。观察组给予甲基多巴及拉贝洛尔联合硫酸镁治疗;对照组给予硝苯地平联合硫酸镁治疗。观察两组治疗疗效、血流动力学指标及不良反应发生率。结果观察组显效率56.1%,总有效率97.6%,均高于对照组(31.7%、82.9%),差异有统计学意义;观察组心脏指数略高于对照组,但差异无统计学意义;观察组MAP,24h pro、TRP和S/D均显著低于对照组,差异有统计学意义;观察组不良反应总发生率为14.6%,显著低于对照组(34.2%),差异有统计学意义。结论甲基多巴及拉贝洛尔联合硫酸镁治疗重度早发型子痫前期综合征效果好,且能减少不良反应发生率,安全性高,值得推广。     

体外冲击波碎石机治疗泌尿系结石568例临床疗效观察

目的探讨体外冲击波碎石机的治疗泌尿系结石的临床疗效。方法回顾性分析该院2008年3月—2011年3月收治的568例结石患者临床资料,所有患者均经体外冲击波碎石机治疗泌尿系统结石。结果经治疗,504例患者结石粉碎后全部排出体外,占88.7%;其中391例一次碎石成功（77.6%）,75例经过2次或3次排石成功（14.9%）,38例经过3次以上排石成功（7.5%）。64例碎石失败,改用其他方法治疗。结论体外冲击波碎石治疗输尿管结石疗效确切、不良反应小、操作方便可行。     

Efficacy,immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6–35 months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres

Background

A quadrivalent split-virion inactivated influenza vaccine (VaxigripTetra?, Sanofi Pasteur; IIV4) containing two A strains (H1N1 and H3N2) and B strains from both lineages (Victoria and Yamagata) was approved in Europe in 2016 for individuals aged?≥?3?years. This study examined the efficacy and safety of IIV4 in children aged 6–35?months.

围手术期综合护理在钬激光碎石取石术治疗女性泌尿结石患者中的应用效果

目的评价围手术期综合护理在钬激光碎石取石术治疗女性泌尿结石患者中的应用效果。方法选取2019年1月至2020年11月在中国科学技术大学附属第一医院西区接受钬激光碎石取石术治疗的80例泌尿结石女性患者,使用随机数字表法将其分为对照组(40例,围手术期常规护理)与观察组(40例,围手术期综合护理),比较两组的护理情况。结果观察组的机体状况评价时间短于对照组,焦虑自评量表(SAS)与抑郁自评量表(SDS)评分低于对照组,差异有统计学意义(P<0.05)。两组的术后并发症总发生率比较,差异无统计学意义(P>0.05)。结论围手术期综合护理的有效运用,能够促进患者康复,改善患者心理状态,减少围手术期护理风险,最终实现临床治疗有效性、可靠性、安全性提升。     

伊来西胺单药治疗儿童癫痫部分性发作的临床疗效及安全性的研究

目的:评价伊来西胺(Ilepcimide)单药治疗儿童癫痫部分性发作的临床疗效及依从性。方法:收集2011年3～9月吉林大学第一医院小儿神经内科门诊癫痫部分性发作的患儿,2～5岁年幼组27例,5～15岁的年长组39例。所有患儿的伊来西胺初始计量均为5 mg·kg-1·d-1,如发作未被控制则每周加量<5 mg·kg-1·d-1,目标剂量为10 mg·kg-1·d-1,最大剂量<300 mg/d。观察期为6月,进行自身对照开放性研究,观察各组的维持期累计疗效,并进行安全性评估。结果:服药3个月后,年幼组的有效率、控制率分别为62.96%、40.74%,年长组的分别为64.10%、41.03%。服药6个月后,年幼组的有效率、控制率分别为77.78%、48.15%;年长组的分别为79.49%、51.28%。66例患儿在服药前及服药后第4周、3和6月时分别查血常规、尿常规、肝功能、肾功能、血液电解质及心电图,各项指标均未见异常改变。15.15%(10/66例)的患儿出现不良反应,主要表现为胃部不适、食欲差或恶心、疲倦、头晕、嗜睡的症状。结论:伊来西胺作为一种新型中药类抗癫痫药物对儿童癫痫部分性发作疗效良好,安全范围大,不良反应少,患者耐受性好,尤其适用伴有其他系统疾病的患者。